As the NHS grapples with unprecedented demand, workforce pressures and growing elective backlogs, agentic automation is emerging as the key practical lever of choice.
Experts from the International Agency for Research on Cancer and the University of Molise chart the impact of the COVID-19 pandemic on cancer treatment.
UK based scientists witnessed how COVID-19 can mutate in a highly vulnerable patient, even when that person is undergoing convalescent plasma treatment.
Paul Barrett, TeleTracking UK, explains how automating patient flow and bed management in real-time can transform hospital operations, free up time for nurses to care, reduce stress on caregivers and importantly improve patient outcomes.
According to data collected by 400 healthcare professionals at the worst moment of the US outbreak, the life support machine that acts in place of the heart and lungs is crucial to reducing COVID-19 deaths for the critically ill.
The American Heart Association found that young, Black adults are more than twice as likely to die in the first year after a heart transplant - in comparison to non-Black transplant recipients of the same age.
Engineers at the University of Bath have published a mathematical model that could help clinicians to safely ventilate two COVID patients on one ventilator.
Data from Queen Mary University of London suggests that Asian COVID patients are 1.5 times as likely to die as white patients - with Black patients 1.3 times more likely to die.
Anna Forsberg, Professor of Transplant Nursing at Lund University and Chair of the ETAHP Committee at the ESOT, explores a key area of development in heart transplant nursing as part of the build-up to ESOT Congress 2021.
A new risk-stratification tool has been developed by researchers from the UK Coronavirus Clinical Characterisation Consortium and can accurately predict the likelihood of deterioration in hospitalised COVID-19 patients.
Here, Mark Clements, MD PhD, paediatric endocrinologist, clinical investigator, and chief medical officer at Glooko Inc. takes part in a Q&A regarding his perspectives on remote clinical trials and data management tools.
Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces ImotopesTM a cutting-edge immunotherapy science with an excellent safety profile that could cure Type 1 diabetes or drastically change treatment options.
